MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered T-Cells take on tough leukemias in early trial
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned or not responded to treatment. The therapy involves taking a patient's own (or a donor's) immune cells, genetically …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 23, 2026 19:23 UTC
-
New radiation-chemo combo aims to boost stem cell transplant success in high-risk leukemia
Disease control TerminatedThis early-stage study tests the safety and best dose of a targeted radiation therapy (TMLI) combined with two chemotherapy drugs before a donor stem cell transplant. It includes 36 people with high-risk acute leukemia or myelodysplastic syndrome (MDS). The goal is to prepare the…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-stage study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The treatment is given with chemotherapy and sometimes an …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New drug combo aims to tame stem cell Transplant's worst side effect
Disease control OngoingThis study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or seve…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC